Mode
Text Size
Log in / Sign up

CT radiomics and transcriptomics predict chemotherapy response in advanced laryngeal cancerNew Scan Predicts Chemo Success Before Treatment Starts

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider radiomics for risk stratification in laryngeal cancer, but await prospective validation.

This retrospective cohort study analyzed 161 advanced laryngeal cancer patients treated with induction chemotherapy to assess the predictive value of CT radiomics features, transcriptomics, and clinical features for chemotherapy response. No comparator was reported, and follow-up duration was not specified. The study setting and publication type were not reported.

Main results showed that a Rad-score had an AUC of 0.715 in the training set and 0.707 in the validation set for discriminating chemotherapy response. Independent predictors of response included Rad-score, gap invasion, and validation, with Rad-score having an odds ratio of 2.89 (95% CI: 1.29–6.48, P=0.010). A Random Forest model combining these features achieved an AUC of 0.914 in the training set, 0.856 in the validation set, and 0.810 in an external test set. Absolute numbers for these outcomes were not reported.

Safety and tolerability data, including adverse events and discontinuations, were not reported. Key limitations include the need for prospective studies to validate clinical utility, as noted in the input. The study suggests this approach may enable precise risk stratification and personalized treatment decisions, potentially sparing non-responders from ineffective therapy, but this is based on observational data and requires further confirmation. Funding and conflicts of interest were not reported.

Imagine standing in a doctor's office waiting for a tough decision. You have advanced laryngeal cancer. The plan is to start chemotherapy immediately. But what if you could know beforehand if that treatment would actually work for you?

That is the hope behind new research. Doctors often struggle to guess which patients will respond well to drugs and which will not. This uncertainty leads to wasted time and unnecessary side effects for those who do not benefit.

Laryngeal cancer affects the voice box. It can make speaking difficult or stop it entirely. Many people with this disease need strong treatment to stop the cancer from growing.

Chemotherapy is a common choice. It attacks fast-growing cells. But it also hurts healthy cells. This causes nausea, fatigue, and hair loss. If a patient does not respond to the drugs, they suffer through these side effects for nothing.

Doctors need a better way to decide. They want to give the right treatment to the right person. Right now, they often guess based on past experience. This is not good enough for such a serious condition.

The surprising shift

For years, doctors looked only at patient history. They checked age, tumor size, and blood tests. These clues were helpful but often incomplete. They could not tell the whole story of how a specific body would react to medicine.

But here is the twist. Scientists now look inside the body using computer scans. They use something called CT radiomics. This technology turns pictures into numbers. It finds tiny patterns in tumors that the human eye cannot see.

Think of a CT scan like a high-resolution photograph of your throat. Normally, you just see the shape of the tumor. Radiomics looks at the texture inside that shape. It counts the brightness, the grain, and the shadows in the image.

Imagine a lock and a key. The cancer is the lock. The chemotherapy is the key. Sometimes the key fits perfectly. Sometimes it does not. Radiomics helps doctors see how well the key fits before they try to turn it.

The study team found four specific patterns in the scans. These patterns act like a score. A high score suggests the drugs will work well. A low score suggests the drugs might not be effective.

Researchers looked at 161 patients who had advanced laryngeal cancer. These patients were getting induction chemotherapy. That is treatment given before surgery or radiation.

The team took CT scans before the drugs started. They extracted over 1,300 features from each image. They used a special math method called LASSO regression to pick the best features.

They built five different computer models. They tested these models on the patients in the study. They also checked the results against a separate group of patients to see if the model held up.

The new model worked very well. It correctly predicted the outcome in 85.6% of the validation group. In a separate test group, it was still 81% accurate.

The most important clue was the radiomics score. Patients with a high score were much more likely to respond to the drugs. The study showed this link was strong and real.

Another important clue was whether the cancer had invaded nearby fat tissue. If the tumor pushed into the fat, the chances of a good response dropped. The computer model combined the scan data with this clinical fact to make its prediction.

But there is a catch

This is where things get interesting. The model is very accurate in the lab. But is it ready for your doctor's office tomorrow? Not yet.

This doesn't mean this treatment is available yet.

The study was done on past data. It is a retrospective look. This means the patients were already treated. The model was built after the fact. We need to prove it works in real-time before we can use it widely.

Doctors say this fits into a bigger picture of precision medicine. The goal is to treat each person as unique. This tool helps move away from a "one size fits all" approach.

It allows doctors to spare patients from ineffective therapy. If the model says a patient will not respond, the doctor can choose a different plan. This saves time and reduces suffering.

If you or a loved one has this cancer, talk to your doctor about new tools. Ask if your hospital uses advanced imaging analysis.

Do not stop your current treatment because of this news. This technology is still in the research phase. It needs more testing to get official approval.

However, it gives hope for better decisions in the future. It means doctors will soon have a clearer map to guide their choices.

The study has some limits. It only looked at 161 patients. That is a small number for such a serious disease. The data came from one group of patients. We do not know if it works for everyone everywhere.

Also, the study used computer models. These are only as good as the data they are given. If the scans are unclear, the model might struggle.

The next step is a prospective study. In this type of study, doctors will use the model before treatment starts. They will see if it predicts outcomes correctly in real life.

If it works, it could change how doctors plan care. It could lead to faster recovery and fewer side effects. Research takes time. We must be patient and careful.

Science moves forward one step at a time. This new tool is a big step toward smarter, kinder care for patients with laryngeal cancer.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundPredicting response to induction chemotherapy (IC) in advanced laryngeal cancer (LC) remains a clinical challenge. This study aimed to develop a non-invasive, interpretable model integrating CT radiomics and clinical features to predict chemotherapy outcomes.MethodsWe retrospectively analyzed 161 advanced LC patients treated with IC. From pre-treatment CT images, 1,321 radiomics features were extracted, and a radiomics score (Rad-score) was constructed using LASSO regression. Transcriptomic analysis explored the biological basis of Rad-score. Independent predictors were identified via multivariate logistic regression and used to build five machine learning models. Model performance was evaluated using AUC, accuracy, and specificity. SHAP analysis was applied to interpret the optimal model.ResultsFour robust radiomics features were selected to construct the Rad-score. The Rad-score demonstrated satisfactory discrimination with an Area Under the Curve (AUC) of 0.715 in the training set and 0.707 in the validation set. In multivariate analysis, the Rad-score (Odds Ratio [OR]=2.89, 95% CI: 1.29–6.48, P = 0.010), gap invasion and validation were identified as independent predictors of chemotherapy response. Among the machine learning models, the Random Forest model achieved the best performance, yielding an AUC of 0.914 in the training set, 0.856 in the validation set, and 0.810 in the external test set. Decision curve analysis confirmed the clinical utility of the model. SHAP analysis confirmed Rad-score and fat space invasion as core predictors, with synergistic effects.ConclusionsWe developed a highly accurate and interpretable Random Forest model that integrates radiomics and clinical features to predict IC response in advanced LC. This tool enables precise risk stratification and personalized treatment decisions, sparing non-responders from ineffective therapy. Prospective studies are needed to validate its clinical utility.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.